SCI 발표논문

SCI 발표논문

← SCI 발표논문 목록

Elife. 2022;11:78636.

Gallbladder adenocarcinomas undergo subclonal diversification and selection from precancerous lesions to metastatic tumors.

, , , , , , , , , , , , , , , , , , , ,

제1저자 강민수, 나희영 · 교신저자 안수민, 김지원

PMID 36476508 PMC9771369 DOI 10.7554/eLife.78636 IF 8.713 혈액종양내과
소속 (9)
  1. Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
  2. Department of Pathology, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
  3. Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
  4. Genealogy Inc, Seoul, Republic of Korea.
  5. Center for Precision Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
  6. Medical Research Collaboration Center, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
  7. Department of Data Science, Dana Farber Cancer Institute, Harvard T.H. Chan School of Public Health, Boston, United States.
  8. Biomedical Research Institute, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
  9. Department of Surgery, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.

Abstract

We aimed to elucidate the evolutionary trajectories of gallbladder adenocarcinoma (GBAC) using multi-regional and longitudinal tumor samples. Using whole-exome sequencing data, we constructed phylogenetic trees in each patient and analyzed mutational signatures. A total of 11 patients including 2 rapid autopsy cases were enrolled. The most frequently altered gene in primary tumors was ERBB2 and TP53 (54.5%), followed by FBXW7 (27.3%). Most mutations in frequently altered genes in primary tumors were detectable in concurrent precancerous lesions (biliary intraepithelial neoplasia [BilIN]), but a substantial proportion was subclonal. Subclonal diversity was common in BilIN (n=4). However, among subclones in BilIN, a certain subclone commonly shrank in concurrent primary tumors. In addition, selected subclones underwent linear and branching evolution, maintaining subclonal diversity. Combined analysis with metastatic tumors (n=11) identified branching evolution in nine patients (81.8%). Of these, eight patients (88.9%) had a total of 11 subclones expanded at least sevenfold during metastasis. These subclones harbored putative metastasis-driving mutations in cancer-related genes such as SMAD4, ROBO1, and DICER1. In mutational signature analysis, six mutational signatures were identified: 1, 3, 7, 13, 22, and 24 (cosine similarity >0.9). Signatures 1 (age) and 13 (APOBEC) decreased during metastasis while signatures 22 (aristolochic acid) and 24 (aflatoxin) were relatively highlighted. Subclonal diversity arose early in precancerous lesions and clonal selection was a common event during malignant transformation in GBAC. However, selected cancer clones continued to evolve and thus maintained subclonal diversity in metastatic tumors.

© 2022, Kang, Na et al.

Keywords

cancer biologycarcinogenesisclonal evolutiongallbladder adenocarcinomageneticsgenomicshumanmetastasis

Figures

Figure 1.
Figure 1. Clinical history of patients, mutational landscape, and study workflow. (A) Clinical history of 11 patients is summarized in the swimmer plot. (B) The mutational landscape of 11 primary tumors (GB) is visualized and compared with the two previous studies on gallbladder adenocarcinoma (GBAC). (C) The process of constructing clonal evolution trajectories using multiple tumor samples is shown in the workflow. Ab, antibody; Abd, abdominal; Adj, adjuvant; BilIN, biliary intraepithelial neoplasia; CBD, common bile duct; CCRT, concurrent chemoradiotherapy; CNVs, copy number variations; COSMIC, Catalogue Of Somatic Mutations In Cancer; FL, 5-fluorouracil + leucovorin; FOLFIRI, 5-fluorouracil + leucovorin + irinotecan; GB, gallbladder; GP, gemcitabine + cisplatin; iFAM, infusional 5-fluorouracil + doxorubicin + mitomycin-C; LOH, loss of heterozygosity; mFOLFOX, modified 5-fluorouracil + leucovorin + oxaliplatin; MSKCC, Memorial Sloan Kettering Cancer Center; NE, not evaluable; SNVs, single nucleotide variants; WGD, whole genome doubling; XP, capecitabine + cisplatin; 5-FU, 5-fluorouracil.
Figure 1—figure supplement 1.
Figure 1—figure supplement 1. Inference of clonal structure by PyClone algorithm. (A–K) The clonal population structure was statistically inferred for GB-A1 (A), GB-S1 (B), GB-S2 (C), GB-S3 (D), GB-A2 (E), GB-S4 (F), GB-S5 (G), GB-S6 (H), GB-S7 (I), GB-S8 (J), and GB-S9 (K) using PyClone. See Supplementary file 2 to check the matching information for the PyClone clusters and the CITUP clones. BilIN, biliary intraepithelial neoplasia; GB, gallbladder; CBD, common bile duct; LN, lymph node.
Figure 1—figure supplement 2.
Figure 1—figure supplement 2. BiIlN and primary gallbladder adenocarcinoma (GBAC) of the GB-S7 patient presumed to be derived from different origins. (A) H&E staining of BiIlN. (B) H&E staining of GBAC. (C) Variant allele frequency of mutated genes in BilIN and primary GBAC. BilIN, biliary intraepithelial neoplasia; H&E, hematoxylin and eosin.
Figure 2.
Figure 2. Spatial and temporal clonal evolution of four patients with gallbladder adenocarcinoma (GBAC) whose precancerous BilIN tissues were analyzed. (A–D) The most probable phylogenetic trees and MapScape and TimeScape results are visualized for GB-A1 (A), GB-S1 (B), GB-S2 (C), and GB-S3 (D). In MapScape visualization (table), the numbers in the row indicate the time taken from diagnosis to tissue acquisition in months, and the columns indicate whether the tissue is a precancerous lesion, primary tumor, or metastatic lesion. Colors represent distinct clones and clonal prevalences per site were proportional to the corresponding-colored area of the cellular aggregate representation. In TimeScape visualization (schema), clonal prevalences (vertical axis) were plotted across time points (horizontal axis) for each clone (colors). Asterisks (*) in the clonal phylogenetic tree denote subclones that constituted <5% in the primary tumor and expanded more than sevenfold in the metastatic tumor. Diamond symbol (◇) is used if the mutation in the figure is classified as 'pathogenic' in Catalogue Of Somatic Mutations In Cancer (COSMIC) v96. Notable events were marked with arrows. The time from diagnosis of GBAC to tissue acquisition was indicated under the sample name. Chemotherapy history was indicated in gray color, where '#' represents the number of chemotherapy cycles. BilIN, biliary intraepithelial neoplasia; CBD, common bile duct; CN, copy number; GB, gallbladder; GP, gemcitabine + cisplatin; LN, lymph node; LOH, loss of heterozygosity.
Figure 3.
Figure 3. Spatial and temporal clonal evolution of additional seven patients with gallbladder adenocarcinoma (GBAC). (A–G) The most probable phylogenetic trees and MapScape and TimeScape results are visualized for GB-A2 (A), GB-S4 (B), GB-S5 (C), GB-S6 (D), GB-S7 (E), GB-S8 (F), and GB-S9 (G). In MapScape visualization (table), the numbers in the row indicate the time taken from diagnosis to tissue acquisition in months, and the columns indicate whether the tissue is a precancerous lesion, primary tumor, or metastatic lesion. Colors represent distinct clones and clonal prevalences per site were proportional to the corresponding-colored area of the cellular aggregate representation. In TimeScape visualization (schema), clonal prevalences (vertical axis) were plotted across time points (horizontal axis) for each clone (colors). Asterisks (*) in the clonal phylogenetic tree denote subclones that constituted <5% in the primary tumor and expanded more than sevenfold in the metastatic tumor. Diamond symbol (◇) is used if the mutation in the figure is classified as 'pathogenic' in Catalogue Of Somatic Mutations In Cancer (COSMIC) v96. Notable events were marked with arrows. The time from diagnosis of GBAC to tissue acquisition was indicated under the sample name. Chemotherapy history was indicated in gray color, where '#' represents the number of chemotherapy cycles. Adj, adjuvant; BilIN, biliary intraepithelial neoplasia; CN, copy number; FL, 5-fluorouracil + leucovorin; GB, gallbladder; GP, gemcitabine + cisplatin; LN, lymph node; LOH, loss of heterozygosity; WGD, whole genome doubling.
Figure 4.
Figure 4. Mutational signature analysis. (A–B) The 100% stacked bar plots compare the proportions of known COSMIC Mutational Signatures v2 within our dataset and two public (MSKCC and Shanhai) datasets (A), and each category split according to the timing of development during clonal evolution (B). The total number of mutations (N) and cosine similarity (CS) values of each category were noted. BilIN, biliary intraepithelial neoplasia; COSMIC, Catalogue Of Somatic Mutations In Cancer; GB, gallbladder; LN, lymph node; MSKCC, Memorial Sloan Kettering Cancer Center.
Figure 4—figure supplement 1.
Figure 4—figure supplement 1. Mutational signatures within each sample from 11 gallbladder adenocarcinoma (GBAC) patients. The 100% stacked bar plots comparing the proportions of known COSMIC Mutational Signatures v2 within each sample from 11 GBAC patients. BilIN, biliary intraepithelial neoplasia; CBD, common bile duct; COSMIC, Catalogue Of Somatic Mutations in Cancer; GB, gallbladder; LN, lymph node.
Figure 4—figure supplement 2.
Figure 4—figure supplement 2. Mutational signatures within each category split according to the type of sample. The 100% stacked bar plots comparing the proportions of known COSMIC Mutational Signatures v2 within each category split according to the type of sample. The total number of mutations (N) and cosine similarity (CS) values of each category were noted. BilIN, biliary intraepithelial neoplasia; COSMIC, Catalogue Of Somatic Mutations In Cancer; GB, gallbladder; LN, lymph node.
Figure 4—figure supplement 3.
Figure 4—figure supplement 3. Mutational signature analysis validated by two additional tools, Signal and MuSiCa. The 100% stacked bar plots comparing the proportions of known COSMIC Mutational Signatures v2 within each category split according to the timing of development during clonal evolution. The total number of mutations (N) and cosine similarity (CS) values of each category were noted. COSMIC, Catalogue Of Somatic Mutations in Cancer.
Figure 5.
Figure 5. ERBB2 copy number variation during neoplastic transformation of BilIN in GB-A1. (A–G) ERBB2 gene amplification (A and B), HER2 SISH (C and D), and HER2 IHC (F and G) were compared between BilIN (A, C) and (F) and primary GBAC (B), (D), and (G) samples and the mean ERBB2/CEP17 ratio of BilIN and GB-A1 samples were compared by using the Wilcoxon rank-sum test (E). BilIN, biliary intraepithelial neoplasia; GBAC, gallbladder adenocarcinoma; IHC, immunohistochemistry; SISH, silver in situ hybridization.

그림 출처: PubMed Central 공개 논문 (PMC9771369)

Conflict of interest statement

MK, HN, SA, JK, SL, SA, JL, JY, HK, KK, KS, JL, SK, JK, YK, KL, YY, JK, JC, HH, JL No competing interests declared

그 밖의 정보
출판 형태
Journal Article, Research Support, Non-U.S. Gov't
저널
eLife · eISSN 2050-084X
전자 출판
2022-12-08
MeSH
Humans · Adolescent · Phylogeny · Gallbladder · Nerve Tissue Proteins · Receptors, Immunologic · Adenocarcinoma* / genetics · Mutation · Precancerous Conditions* / genetics · Bile Pigments · Ribonuclease III · DEAD-box RNA Helicases
Substances
Nerve Tissue Proteins · Receptors, Immunologic · Bile Pigments · DICER1 protein, human · Ribonuclease III · DEAD-box RNA Helicases
데이터
SRA: PRJNA821382
참고문헌
64편